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1  | INTRODUC TION
Systemic sclerosis (SSc), or scleroderma, is defined as a systemic 
connective tissue disease characterized by autoimmune and vas-
cular manifestations ultimately leading to organ fibrosis.[1] Like 
most autoimmune diseases, SSc develops on a genetically predis-
posed background (the polymorphisms that have been identified 
concern mostly the immune system) and is probably triggered 
by environmental factors. However, the interplay between the 
vascular, immune, and fibrotic components remains poorly un-
derstood and no real breakthrough has been made in terms of 
targeted treatments. The classical pathophysiological features 
as well as the underlying molecular processes are presented in 
Figure 1.
Skin manifestations, which give the name to the disease, are 
considered as diagnostic, subclassification, severity and prognosis 
markers.[2] SSc skin effectively recapitulates the main pathogenic 
processes of the disease, namely fibrosis, vasculopathy and inflam-
mation. Moreover, evidence emerges that key events initiating the 
disease could take place in the skin, whereas “inside- out” or even 
“outside- in” as in the field of atopic dermatitis.[3] Besides classically 
known features affecting the dermis, skin features also include var-
ious types of pigmentary disorders, which affect up to half of the 
patients, such as perifollicular depigmentation[4] or diffuse hyper-
pigmentation.[5] A recent study from our group found a significant 
association between diffuse hyperpigmentation and vascular in-
volvement in SSc, particularly digital ulcers.[6] Current knowledge of 
SSc epidermal features includes overexpression of PDGR- β, which 
was the starting point for targeting the PDGF- pathway.[7] Another 
aspect is abnormal terminal differentiation, with an altered expres-
sion of key proteins of the barrier, such as involucrin, loricrin and 
filaggrin.[8] The skin barrier function could be altered through the 
increase of IL- 31,[9] which has been shown in vivo to be responsible 
for transepidermal water loss (TEWL) .[10] However, TEWL seems 
not altered in SSc skin.[11]
Paradoxically, skin manifestations have not been thoroughly in-
vestigated as possible indicators of actionable targets. Deciphering 
the molecular mechanisms behind skin features could be applicable 
to other organs and of importance for SSc, particularly from a ther-
apeutic point of view.
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Abstract
Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease combin-
ing inflammatory, vasculopathic and fibrotic manifestations. Skin features, which give 
their name to the disease and are considered as diagnostic as well as prognostic 
markers, have not been thoroughly investigated in terms of therapeutic targets. CCN 
proteins	(CYR61/CCN1,	CTGF/CCN2,	NOV/CCN3	and	WISP1-	2-	3	as	CCN4-	5-	6)	are	
a family of secreted matricellular proteins implicated in major cellular processes such 
as cell growth, migration, differentiation. They have already been implicated in key 
pathophysiological processes of SSc, namely fibrosis, vasculopathy and inflamma-
tion. In this review, we discuss the possible implication of CCN proteins in SSc patho-
genesis, with a special focus on skin features, and identify the potential actionable 
CCN targets.
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In this context, taking aim at the CCN family of matricellular pro-
teins could be promising, as they are implicated in key pathophysio-
logical processes in SSc as well as in skin homoeostasis. This family 
of six matricellular proteins plays critical regulatory roles in inflam-
mation, angiogenesis and wound healing.[12–16] Initially identified as 
growth factors,[17–19] they have been shown to be involved in several 
major cellular processes such as cell growth, adhesion, migration and 
extracellular matrix homoeostasis.
The first member of the CCN family (CYR61 for cysteine- rich 
angiogenic protein 61) was initially characterized in 1990 in the 3T3 
murine cell line, as a an immediate early gene whose transcription 
was triggered within a few minutes upon serum stimulation.[17] 
Along this line, CTGF (connective tissue growth factor) was rap-
idly	identified	in	human	endothelial	cells	(HUVEC)	using	PDGF-	IgG	
affinity chromatography.[18]	NOV	(nephroblastoma	overexpressed)	
was discovered in chicken while sequencing the flanking sequences 
of a virus used to induce nephroblastoma.[19] The conserved pri-
mary sequence, as well as the similar tetramodular organization of 
CYR61,	 CTGF	 and	NOV,	 led	 to	 their	 designation	 as	 CCN	 (an	 ac-
ronym coined from the first letter of the three names) family of 
proteins.[20] Soon after, WISP1/ CCN4 (WNT1 inducible signalling 
pathway protein 1), WISP2/ CCN5 and WISP3/CCN6 were discov-
ered as upregulated in a mouse mammary epithelial cell line after 
Wnt- 1 induction.[21] Due to their similar multimodular structure 
(except CCN5, which lacks the C- terminal module), WISP proteins 
were integrated into the CCN family of proteins.[22] The common 
structure as well as binding sites for proteins of interest in SSc is 
presented in Figure 2.
Characterization of CCN proteins in human skin rapidly followed, 
both at the cellular and tissue level, as well as the transcriptional and 
protein level.[23–25] Total skin transcriptomic analysis showed that 
CCN5 is the most abundantly expressed CCN member in healthy 
skin in vivo, followed by CCN2, then CCN3 and CCN1.[24]
Roles of CCN proteins are difficult to characterize due to sev-
eral factors: ubiquitous expression, multimodular organization, dif-
ferent isoforms; from a functional point of view, they can act on a 
wide range of cellular processes, and sometimes present overlapping 
functions. To date, most studies in the scleroderma field focus on 
the first three family members (CCN1- 3) and on specific cellular pro-
cesses or tissues. A summary of the expression of CCN proteins in 
healthy and SSc skin can be found in Table 1.
In this review, we discuss the role of CCN proteins in the key 
pathophysiological processes of SSc, with a special focus on skin 
features and their implication as potential new targets for therapies.
2  | CCN PROTEINS IN FIBROSIS
One	of	 the	most	 studied	actors	 in	SSc	 is	CCN2,	 a	major	mediator	
of various fibrotic conditions including skin, heart, lung, liver and 
kidney.[26] CCN2 is increased in SSc skin, both at the mRNA level 
and at the protein level. CCN2 is also upregulated in SSc fibroblasts 
(mRNA).[27] It is elevated in the serum [28] and correlated with the 
severity of skin and lung fibrosis. Moreover, polymorphisms of 
the CCN2 gene have been found to be associated with SSc.[29,30] 
CCN2 itself is not sufficient to induce fibrosis in a mouse model.[31] 
However, it is needed for the maintenance of fibrosis when induced 
by TGF- β,[32,33] by promoting fibroblast adhesion to ECM compo-
nents.[34] Indeed, CCN2 is part of an autocrine profibrotic loop, 
independent of TGF- β, initiated by endothelin- 1 and inducing fibro-
blasts to synthetize and contract ECM.[14,27] In this context, CCN2 
acts by enhancing adhesive responses to TGF- β and endothelin- 1 
in fibroblasts, downstream of the antifibrotic protein PTEN (phos-
phatase and tensin homologue).[35] PTEN, which is reduced in SSc 
skin fibroblasts,[36] acts by suppressing PI3K- Akt signalling (phos-
phatidylinositol 3- kinase (PI3K) and Akt/Protein Kinase B).[37] Its 
fibroblast- specific loss in an in vivo model induces collagen depo-
sition in the lung in a CCN2- dependent manner.[38]	Overall,	 inacti-
vation of CCN2 is a promising lead—more specific than a targeted 
TGF- β therapy—in antifibrotic therapies: notably, fibroblast- specific 
ablation of CCN2 reduces skin fibrosis in the bleomycin mouse 
model.[33]
CCN3 counteracts CCN2 profibrotic pathway, although this 
has never been demonstrated directly in the skin. In the kidney, 
CCN3 is upregulated in response to TGF- β signalling as shown by 
several studies of diabetic renal fibrosis and is regulated in an op-
posite manner to CCN2.[39,40] Treatment with recombinant CCN3 
succeeded in reducing glomerular fibrosis in a mouse model of di-
abetic nephropathy, showing a capacity to reverse the disease.[41] 
F IGURE  1 Three pathogenetic processes of systemic sclerosis 
and major affected signalling pathways. Activated pathways 
or increased molecules are represented in red. Downregulated 
pathways or decreased molecules are represented in blue
F IGURE  2 Linear structure of CCN proteins and binding sites 
for proteins of interest in Systemic sclerosis (SSc) pathophysiology. 
Ligands that are increased or upregulated in SSc are represented in 
red. Ligands that are decreased or downregulated are represented 
in blue
     |  13HENROT ET al.
The antifibrotic effect of CCN3 could work through the regulation 
of multiple pathways, possibly via repression of CCN2 but also 
CCN4.[42] Moreover, CCN3 overexpression in a mouse fibroblast 
cell line blocked TGFβ- and Wnt- regulated profibrotic gene ex-
pression.[12]	Of	note,	CCN3	mRNA	has	been	found	to	be	increased	
in SSc skin.[12]
The role of CCN1 has not been extensively studied in fibrosis, al-
though its role in promoting tissue repair in wound healing is becom-
ing clearer.[13]	One	study	has	found	that	CCN1	is	induced	in	dermal	
fibroblasts by TGF- β along with CCN2 and α- SMA.[43]
CCN5 is the most abundant CCN in the dermis in terms of mRNA 
expression.[25] Contrary to CCN2, CCN5 has been found to be 
downregulated after TGF- β exposure in human skin fibroblasts.[44] 
Moreover, CCN2 and CCN5 present an opposite expression pattern 
in vascular smooth muscle cells (although they have not been studied 
together).[45] However, no study has been conducted to characterize 
the expression of CCN5 in SSc.
Little is known concerning the role of the other CCN proteins in 
skin. CCN4 has been identified in skin fibroblasts and seems to play 
role in a paracrine manner, by binding to decorin and biglycan.[46] 
Moreover, CCN4 has been shown to regulate wound healing by 
modulating proliferation, migration and ECM expression in dermal 
fibroblasts via α5β1 integrin and TNFα.[47]
3  | CCN PROTEINS IN ANGIOGENESIS 
AND VA SCULOPATHY
CCN1, 2 and 3 are all known as proangiogenic. In particular, CCN1 
and CCN2 are important actors in endothelial cells homoeostasis, 
working at least partly through binding to cell surface integrins; their 
expression	in	endothelial	cells	is	enhanced	by	VEGF.[48] However, al-
though the role of CCN2 role in SSc is well- documented, CCN1 and 
CCN3 have been less studied in scleroderma.
CCN1 is known to enhance tubule formation in vitro via inte-
grin α6β1 and integrin αvβ3.[49] CCN1 has been implicated in SSc 
impaired angiogenesis in a recent study,[50] showing that CCN1 ex-
pression was markedly decreased in dermal microvessels of patients 
with SSc as well as in the serum of SSc patients with digital ulcers. 
Another recent study showed that simultaneous knock- down of his-
tone deacetylase 5 and CCN1 inhibited in vitro angiogenesis, while 
overexpressing CCN1 in SSc endothelial cells led to increase in tube 
formation,[51] suggesting that a decrease in CCN1 plays an important 
functional role in SSc impaired angiogenesis.
In vitro, CCN2 effectively recapitulates angiogenic events by 
promoting endothelial cell adhesion, migration, proliferation and 
tubule formation.[52] In vivo, CCN2 enhances neovascularization in 
a mouse model of retinopathy.[53] However, recent in vitro studies 
TABLE  1 CCN proteins in human skin and expression in SSc
CCN member Synonym (human)
Healthy skin SSc skin
Skin expression (mRNA 
level)[25]
Main producing skin cells in 
vivo[25,76]
Skin expression 
(mRNA level)
Expression in SSc 
skin cells
CCN1 CYR61 Weak in epidermis and dermis Fibroblasts, endothelial cells Decreased[50] Decreased in 
endothelial cells 
in situ, but 
unchanged in 
fibroblasts in 
vitro[50]
CCN2 CTGF Strong in dermis > Epidermis Melanocytes > Fibroblasts, 
endothelial cells
Increased[86] Increased in 
fibroblasts, 
endothelial cells 
and keratino-
cytes in situ and 
in vitro[8,87,88]
CCN3 NOV Dermis > Epidermis Keratinocytes > Fibroblasts, 
endothelial cells, eccrine 
sweat glands
Melanocytes
Increased[12] or 
unchanged [86]
Decreased in 
endothelial cells 
in situ and in 
vitro, and in 
fibroblasts in 
vitro (unpub-
lished data)
CCN4 WISP1 Weak in epidermis and dermis Fibroblasts, endothelial cells 
(?) 47,89
ND ND
CCN5 WISP2 Strong in dermis > Epidermis Differentiated keratinocytes 
> Endothelial cells, 
fibroblasts
Decreased? [86] ND
CCN6 WISP3 Weak in epidermis and dermis ND ND ND
mRNA, messenger RNA; ND, not described.
Expression in SSc skin cells: compared to healthy control cells.
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using cells and tissues from the CCN2- null mouse eye did not in-
dicate any effect of CCN2 deletion on neovascularization and an-
giogenesis. This finding suggests that CCN2 may be tissue- specific 
concerning angio/vasculogenesis, possibly via interaction with 
VEGF.[54]	 Moreover,	 the	 results	 from	 the	 knock-	out	 (KO)	 stud-
ies could indicate that the upregulation of CCN2 observed in SSc 
is mainly responsible for enhanced fibrosis and is not sufficient to 
correct vascular dysfunction. Accordingly, we have observed a de-
crease in CCN2 expression in cultured SSc endothelial cells, whereas 
an increase was observed in SSc fibroblasts (unpublished data).
CCN3 has been shown to be proangiogenic in several stud-
ies: addition of recombinant CCN3 to rat corneas induces 
TABLE  2 Phenotypes of genetically modified mouse models
CCN 
mem-
ber
Knock- in (KI) Knock- out (KO)
RefFibrosis Vasculopathy Inflammation Other Fibrosis Vasculopathy Inflammation Other
CCN1 Increased 
fibrosis
ND Lung 
alveolitis, 
decreased 
TNF- α- 
mediated 
apoptosis
Weight loss and 
higher 
mortality; (KI 
of 
senescence- 
defective 
mutant CCN1)
ND Placental vascular 
insufficiency and 
compromised 
vessel integrity
ND Embryonic 
lethal, 
chorio- 
allantoic 
fusion 
(30% 
mice)
61,75,90,91
CCN2 Increased 
cardiac 
fibrosis in 
response to 
pressure 
overload
KI fibroblast- 
specific: skin, 
lung, kidney, 
and small 
arteries 
fibrosis
ND ND Embryonic 
lethal if 
ninefold 
overexpres-
sion
ND Abnormal growth 
plate 
angiogenesis
ND Perinatal 
lethal: 
severe 
skeletal 
and 
pancreatic 
abnormali-
ties, 
pulmonary 
hypoplasia
92–97
CCN3 ND ND ND Overexpression	
in fibroblasts: 
osteopenia 
(skin and 
vessels not 
analysed)
ND Vascular	conges-
tion in kidney and 
liver; enhanced 
neointimal 
hyperplasia in 
response to 
endothelial injury
ND Viable:	
modest 
skeletal 
and 
cardiac 
abnormali-
ties, 
muscle 
atrophy 
and 
cataract
98–100
CCN4 ND Increased 
intimal 
thickening 
due to 
smooth 
muscle cell 
migration
ND ND Delayed 
wound 
healing, 
reduced 
collagen 
expres-
sion
ND ND Impaired 
motor 
coordina-
tion
47,59,101
CCN5 Decreased 
cardiac 
fibrosis in 
response to 
pressure 
overload
ND ND ND ND Hyperproliferation 
of vascular 
smooth muscle 
cells in response 
to injury
ND Both 
reported: 
early 
embryonic 
lethality 
and 
normal 
pheno-
type
45,97,102,103
CCN6 Normal Normal Normal Normal 
phenotype
Normal Normal Normal Normal 
pheno-
type
104,105
ND, not described.
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neovascularization[55]; CCN3 is highly expressed at a basal state in 
endothelial cells and is implicated in vascular repair as well as in-
duced	in	HUVECs	by	laminar	shear	stress.[15,56] The mechanism un-
derlying its proangiogenic action is probably at least partly mediated 
by binding to several integrins such as αvβ5.
[57] Interestingly, CCN3 
and CCN1 are decreased in placental endothelial cells of women 
suffering from preeclampsia, a pathological pregnancy condition 
characterized by hypoxic vascular lesions.[58] The pathophysiol-
ogy underlying  preeclampsia is strikingly similar to SSc renal crisis. 
Unpublished data from an ongoing study of our group focusing on 
human microvascular dermal endothelial cells point towards an im-
portant role for CCN3 in angiogenesis in vitro.
Last, CCN4 promotes vascular smooth muscle cells migration in 
vitro via an integrin- dependent pathway,[59] but its action has not 
been studied in the vascular SSc system.
4  | CCN PROTEINS IN DERMAL 
INFL AMMATION AND AUTO IMMUNIT Y
A growing body of evidence supports the concept that CCN1 as a 
pro- inflammatory factor in skin. In the dermis, CCN1 is elevated dur-
ing the inflammatory phase of wound healing and downregulated 
during the extracellular matrix remodelling phase.[24] CCN1 has also 
been shown to regulate macrophage function during inflammation 
in mice, by supporting macrophage adhesion as well as upregulat-
ing pro- inflammatory cytokines such as TNF- α.[60] Moreover, CCN1 
is able to activate the cytotoxic potential of TNF- α and thus to in-
duce fibroblast apoptosis.[61] Interestingly, CCN1 is highly produced 
by thymic epithelial cells and boosts T- cell production in mice.[62] 
Several studies have found an overexpression of CCN1 in the epi-
dermis of inflammatory skin conditions such as psoriasis, where it 
promotes the production of pro- inflammatory mediators such as IL- 
8,[63] IL- 1β[64] or CCL- 20.[65]
CCN3 is present at high levels in the supernatant of T regulatory 
lymphocytes in the central nervous system, where it promotes oligo-
dendrocyte differentiation and myelination.[66] Preliminary data from 
our team indicate high production of CCN3 by lymphocyte infiltrating 
the dermis in vitiligo. Moreover, CCN3 expression is regulated by TNF- α 
and IL- 1,[67] and CCN3 physically interacts with IL33,[68] a T- helper- 2 as-
sociated cytokine able to induce fibrosis in SSc.[69]
Similar to CCN3, CCN6 gene expression is induced by TNF- α and 
IL- 1; of note, CCN6 is overexpressed in the synovial tissue of patients 
suffering from rheumatoid arthritis.[70] However, such observations 
have not been made in the skin.
5  | CCN PROTEINS AND ACCELER ATED 
AGEING
There is increasing evidence that SSc skin presents several hallmarks 
of cellular ageing, such as enhanced production of reactive oxygen 
species	(ROS),	methylation	abnormalities	and	impaired	autophagy.[71] 
CCN1 has been associated with skin ageing in several studies.[72–75] 
Notably,	it	has	been	shown	to	upregulate	ROS	production	and	induce	
skin fibroblasts senescence by binding to integrin α6β1 and heparin 
sulphate proteoglycan during wound repair.[75]	Of	note,	knock-	in	(KI)	
mice for a mutant CCN1 lacking the α6β1 integrin- binding (so- called 
senescence- defective CCN1) showed exacerbated fibrosis in wound 
healing. Another study implicates CCN1 in aberrant collagen homoe-
ostasis associated with dermal fibroblasts senescence, suggesting an 
important role for CCN1 in collagen loss.[72] Indeed, CCN1 is a known 
regulator of type I collagen production and degradation.[73]
6  | CCN PROTEINS IN PIGMENTATION
CCN3 mRNA is the most highly expressed CCN gene in the epider-
mis.[25] Its role in epidermal homoeostasis and particularly pigmen-
tation regulation remains unclear. Its epidermal expression seems 
to be increased in pigmented phototypes[76] (interestingly, CCN5 
seems to vary inversely). CCN3 plays a major role in melanocyte ho-
moeostasis and is implicated in melanocyte adhesion.[67] Conversely, 
downregulation of CCN3 in melanocytes results in cell detachment 
from the epidermis in vitro and could be implicated in pigmentary 
disorders such as vitiligo.[77] To date, however, the implication of 
CCN3 in the development of pigmentary changes often observed in 
SSc has not been proven.
UV	radiation	upregulates	CCN1	and	CCN2	expression	in	whole	
skin	in	vivo,	whereas	UV	radiation	downregulates	CCN3,	4,	5	and	
CCN6 expression, at the mRNA level.[24] Interestingly, CCN1 has 
recently been found to stimulate melanogenesis through integrin 
α6β1 binding as well as p38 MAPK and ERK1/2 signalling.[78] The 
authors suggested that CCN1 is a fibroblast- derived melanogenic 
paracrine	mediator,	 secreted	under	UVB	 irradiation.	This	 finding,	
along with the role of CCN1 in accelerated ageing, could be consis-
tent with the “photoageing” pattern observed in some SSc patients.
7  | CCN PROTEINS IN EPIDERMAL 
DIFFERENTIATION
CCN2 is increased in the epidermis of SSc patients, particularly in 
the basal membrane.[8] This increase was predominantly seen in re-
cent SSc (< 2 years). Accordingly, CCN2 expression has been shown 
to be induced by TGF- β in human keratinocytes.[79] CCN2 is also 
thought to regulate keratinocyte migration via the RAS- MEK- ERK 
pathway.[80]
Differential expression of CCN3 and CCN5 within epider-
mal layers also suggests that these factors are associated with 
epidermal differentiation, although the precise mechanism is 
unknown to date.[25] CCN3 expression is reported as nuclear or 
perinuclear in basal keratinocytes, as opposed to cytoplasmic 
in the upper layers, whereas CCN5 expression is reported weak 
and perinuclear in the basal layer and strong and cytoplasmic in 
the upper layers.
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8  | CCN PROTEINS IN ANIMAL MODEL S: 
WHAT C AN WE LE ARN ABOUT KE Y 
PATHOPHYSIOLOGIC AL PROCESSES OF 
SSC?
Knock-	out	(KO)	and	knock-	in	(KI)	animal	models	provide	relevant	
information concerning the role of CCN proteins in key patho-
physiological	 processes	 of	 SSc.	 The	 KO	 models	 interestingly	
point out the major role of CCN1 and CCN2 (and to a lesser ex-
tent CCN3 and CCN5) in vasculogenesis. Moreover, CCN1 and 
CCN2 seem to play a prominent role in fibrosis regulation, CCN1 
being responsible for wound- healing resolution and CCN2 for a 
persistent fibrotic phenotype as shown by the KI models. CCN5 
also appears as an antifibrotic molecule. Lastly, CCN1 seems to be 
an important actor in inflammatory processes. Surprisingly, CCN4 
may come off both as a proangiogenic protein and as a antifi-
brotic protein, which makes it an interesting actor in scleroderma. 
A summary of the phenotypes of transgenic mice models is found 
in Table 2.
9  | ARE CCN PROTEINS POTENTIAL 
DRUGGABLE TARGETS IN SSC?
Since CCN proteins are downstream effectors, they could be ther-
apeutically targeted without affecting major upstream signalling 
pathways. However, very few studies have reported the use of 
anti- CCN antibodies in preclinical studies, and the proof of concept 
remains to be obtained. Figure 3 summarizes the potential roles of 
CCN proteins in SSc pathways and suggested targets for therapy.
Recently, a monoclonal antibody against CCN2 (FG- 3019) has 
been shown to inhibit skin fibrosis in the angiotensin- II induced SSc 
mouse model.[81] In this study, the intraperitoneal injection of FG- 
3019 (concomitant to Ang- II injection) significantly reduced dermal 
thickness and collagen content in skin from Ang- II challenged mice, 
as well as the number of αSMA- positive cells, PDGFRβ and procol-
lagen	expression	 in	 the	upper	dermis.	Of	note,	 the	same	antibody	
has been tested in an open- label phase II clinical trial designed for 
patients suffering from idiopathic pulmonary fibrosis.[82] For one 
third of treated subjects, pulmonary function improved as well as 
lung fibrosis. A randomized placebo- controlled phase 2 clinical trial 
is currently underway.
Since CCN1 is pivotal for many pathophysiological pathways of 
SSc, a CCN1- based therapy, whether topical or systemic, could also 
be promising for SSc. Topical application of CCN1 has indeed shown 
to reverse the enhanced fibrosis of cutaneous wounds in the α6β1 
integrin- binding defective CCN1- KI mice.[75] Conversely, a neutral-
izing anti- CCN1 polyclonal antibody inhibited angiogenesis in an 
oxygen- induced retinopathy mouse model[83] as well as a bone frac-
ture mouse model.[84] A monoclonal neutralizing antibody against 
CCN4 has also been used in a murine model of pulmonary fibrosis 
and showed promising results in reducing the expression of genes 
implicated in fibrosis and epithelial- to- mesenchymal transition.[85] 
However, these two antibodies have never been used, to our knowl-
edge, in the skin or for scleroderma. Finally, a recombinant CCN3 
has been used successfully in a mouse model of renal fibrosis[41] and 
could be considered for skin issues.
In conclusion, knowledge gained from studies of the roles of CCN 
proteins in dermal and epidermal biological processes can be appli-
cable for other organs. Moreover, due to multiple functions of CCN 
protein, effective therapeutic strategies may rely on downregulating 
or upregulating specific CCN proteins in SSc. Based on emerging ev-
idence, there is a growing need to systematically determine the roles 
of all CCN family members in the pathophysiological pathways that 
are characteristic of scleroderma skin. SSc models provide an ideal 
opportunity to test the concept of therapeutic targeting of CCN pro-
teins for the treatment of SSc.
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F IGURE  3 CCN proteins as potential druggable targets 
in Systemic sclerosis (SSc). Plain arrows: actual therapies, 
dotted arrows: proposed therapies; red: downregulation, blue: 
upregulation. R = recombinant, Ab = antibody. CCN proteins are 
dysregulated at various levels in SSc skin. CCN2 is increased in the 
dermis, and the epidermis and monoclonal antibodies against CCN2 
have been tested in preclinical studies. CCN1 is decreased in dermal 
blood vessels, and thus, SSc patients could benefit from therapies 
based on recombinant CCN1. CCN3 is decreased in dermal blood 
vessels (unpublished data). Therapies based on recombinant CCN3 
could reduce vascular abnormalities. Little is known about the 
expression of other CCN family members in SSc skin
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